Page last updated: 2024-08-21

quinazolines and bicalutamide

quinazolines has been researched along with bicalutamide in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chmurzyska, W; Dudkowska, M; Grzelakowska-Sztabert, B; Manteuffel-Cymborowska, M; Stachurska, A1
Barrow, D; Dutkowski, CM; Goddard, L; Harper, ME; Jones, HE; Nicholson, RI; Smith, C1
Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM1
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C1
Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Martella, O; Muzi, P; Ronchi, P; Vicentini, C1
Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V1
Azad, AA; Beardsley, EK; Chi, KN; Chin, J; Ellard, SL; Hotte, SJ; Klotz, L; Kollmannsberger, C; Mukherjee, SD1

Trials

1 trial(s) available for quinazolines and bicalutamide

ArticleYear
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2014

Other Studies

6 other study(ies) available for quinazolines and bicalutamide

ArticleYear
Cross-talk between steroid-receptor-mediated and cell-membrane-receptor-mediated signalling pathways results in the in vivo modulation of c-Met and ornithine decarboxylase gene expression in mouse kidney.
    The Biochemical journal, 2001, Jan-15, Volume: 353, Issue:Pt 2

    Topics: Androgen Antagonists; Anilides; Animals; Female; Folic Acid; Folic Acid Antagonists; Gene Expression Regulation; Hepatocyte Growth Factor; Kidney; Male; Mice; Nitriles; Ornithine Decarboxylase; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Cell Surface; Receptors, Steroid; Signal Transduction; Testosterone; Tosyl Compounds

2001
Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.
    The Prostate, 2001, Sep-15, Volume: 49, Issue:1

    Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Division; Drug Interactions; Enzyme Inhibitors; ErbB Receptors; Humans; Immunohistochemistry; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured

2001
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12

    Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2002
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    International journal of cancer, 2005, Jul-01, Volume: 115, Issue:4

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous

2005
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
    Oncology reports, 2007, Volume: 18, Issue:5

    Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tosyl Compounds

2007
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
    The Prostate, 2011, Oct-01, Volume: 71, Issue:14

    Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays

2011